Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma
Abstract
Cervical cancer is the second most common cancer in women worldwide. Human papillomavirus (HPV) is the etiologic agent for the vast majority of premalignant and malignant lesions, and high‐risk HPV types can be detected in almost all cases of cervical dysplasia and carcinoma. HPV testing has been widely adopted for the triage of patients after a cervical cytology screening test (Papanicolaou smear or liquid‐based cervical cytology such as ThinPrep or SurePath) interpretation of atypical squamous cells of undetermined significance (ASCUS), and HPV testing is increasingly used for screening in conjunction with cervical cytology. Although cervical cytology is a highly effective screening test for cancer, it has limited specificity for clinically significant lesions in cases with low‐grade cytologic abnormalities. Up to a quarter of all patients may have a false‐negative result on the basis of cervical cytology testing alone. This review focuses on HPV testing methods and molecular markers and their clinical relevance. HPV testing and surrogate molecular markers of HPV infection (p16INK4a) may help identify cases that are associated with underlying high‐grade premalignant or malignant lesions and may also reduce aggressive treatment of patients with low‐grade lesions. Cancer (Cancer Cytopathol) 2007;. © 2007 American Cancer Society.Keywords
This publication has 128 references indexed in Scilit:
- Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled TrialJNCI: Journal of the National Cancer Institute, 2006
- Development of a Sensitive and Specific Assay Combining Multiplex PCR and DNA Microarray Primer Extension To Detect High-Risk Mucosal Human Papillomavirus TypesJournal of Clinical Microbiology, 2006
- Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical SamplesJournal of Clinical Microbiology, 2006
- HPV testing in cervical screeningBest Practice & Research Clinical Obstetrics & Gynaecology, 2006
- Atypical Glandular Cells: New Bethesda Terminology and Management GuidelinesObstetrical & Gynecological Survey, 2003
- Overexpression of p16INK4A in liquid‐based specimens (SurePath™) as marker of cervical dysplasia and neoplasiaDiagnostic Cytopathology, 2002
- Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervixCancer, 2001
- Cancer Cell CyclesScience, 1996
- Hand-genital transmission of genital warts? An analysis of prevalence dataEpidemiology and Infection, 1995
- Herpes simplex virus type 2: A possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancerInternational Journal of Cancer, 1991